---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-031327"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-06-30T21:19:20+00:00"
generated_at: "2026-06-30T21:20:06.312487+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# bioAffinity reports 300% YoY CyPath Lung sales growth in April; partners with Philips for veteran screening

## Summary
- CyPath Lung unit sales in April 2026 increased nearly 300% vs. April 2025; ordering physician sites up 69% Q1 2025 to Q1 2026.
- Collaboration with Philips to enhance lung cancer screening for U.S. veterans using mobile CT, CyPath Lung, and 4DMedical software.
- Pilot study with Brooke Army Medical Center underway for asthma/COPD companion diagnostics using flow cytometry+AI.
- Preclinical research shows siRNA silencing selectively kills squamous skin cancer cells, suggesting topical treatment for basal/squamous cell carcinomas.
- Recent news includes Mexico patent allowance for CyPath Lung technology and record monthly sales in April 2026.

## SEC filing metadata
- accession: 0001493152-26-031327
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-06-30T21:19:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226031327/0001493152-26-031327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226031327/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-031327
- JSON: https://secwatch.observer/filing/0001493152-26-031327.json
- Plain text: https://secwatch.observer/filing/0001493152-26-031327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.